The above established dual EV-RNA and EV-protein mutational profiling was applied to analyze EVs from blood plasma in a cohort of ten metastatic NSCLC patients with at least one known sensitizing EGFR mutation based on primary tumor biopsy. This evidence concerns the gene EGFR and neoplasm.